TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20598969

Group type: EXPERIMENTAL
Intervention: Fibrinolysis combined with enoxaparin, clopidogrel, and aspirin, followed by cardiac catheterization within 6 to 24 hours or rescue coronary intervention if reperfusion fails within 90 minutes of fibrinolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary PCI performed according to local guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinolysis combined with enoxaparin, clopidogrel, and aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 0
Study: 18452763

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16643559

Group type: EXPERIMENTAL
Intervention: Topiramate (25 mg daily increment over 1 week to 50 mg for 2 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sodium valporate (200 mg daily increment over 1 week to 400 mg for 2 months)
Number of subjects: 64
Study: 12600850

Group type: COMPARATOR
Intervention: Butter meal (100 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Olive oil meal (80 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control meal (energy-free soup with 50 g carbohydrate)
Number of subjects: 12
Study: 11268452

Group type: EXPERIMENTAL
Intervention: Cisplatin (5 x 20 mg/m2) over 5 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cisplatin (1 x 50 mg/m2) plus ifosfamide (4 g/m2) as a single-day infusion
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with carboplatin (3 x 500 mg/m2) and ifosfamide (3 x 4 g/m2) over three days
Number of subjects: 52
Study: 8752238

Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation
Number of subjects: 197

Group type: COMPARATOR
Intervention: Nonintervention (awaiting spontaneous labor)
Number of subjects: 197
Study: 1373064

Group type: EXPERIMENTAL
Intervention: Isoprinosine (1 g orally three times a day for 24 weeks)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Isoprinosine and Placebo
Number of subjects: 642
Study: 6397652

Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 31486068

Group type: EXPERIMENTAL
Intervention: Use of hearing aids (HAs)
Number of subjects: 114862
Study: 29096522

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine by infusion
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26946613

Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy plus compound Kushen injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Only radiochemotherapy (Control)
Number of subjects: 60
Study: 25196631

Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Medication (ketoprofen tablet thiocolchicoside capsule 2 × 1 for 7 days)
Number of subjects: 63
Study: 22432105

Group type: EXPERIMENTAL
Intervention: Insulin therapy initiated in 855 patients
Number of subjects: 4900

Group type: COMPARATOR
Intervention: Placebo (nonintervention arm)
Number of subjects: 4900
Study: 19022418

Group type: EXPERIMENTAL
Intervention: Resistive flywheel exercise (FW)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg i.v.)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bed rest only (Ctrl)
Number of subjects: 25
Study: 17761409

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid and docosahexaenoic acid supplementation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 15115904

Group type: EXPERIMENTAL
Intervention: Combination therapy (carvedilol + enalapril)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 572

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 572
Study: 12239447

Group type: EXPERIMENTAL
Intervention: Vinblastine (VBL) 0.15 mg/kg i.v. every 2 weeks and Interferon-gamma (IFN-gamma) 100 microg s.c. 3 times weekly (Trial 1)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vinblastine (VBL) 0.15 mg/kg i.v. every 2 weeks, Interferon-gamma (IFN-gamma) 100 microg s.c. 3 times weekly, and oral 13-cis retinoic acid (13-CRA) 40 mg/day (Trial 2)
Number of subjects: 69
Study: 9846584

Group type: EXPERIMENTAL
Intervention: Presence of Pro(7) polymorphism in NPY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pro(7) polymorphism in NPY
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leu(7)/Leu(7) polymorphism in NPY
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPY polymorphism
Number of subjects: 0
Study: 8031029

Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 800 mg of ofloxacin daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin, 100 mg of dapsone, and 50 mg of clofazimine daily plus 300 mg of clofazimine once every 28 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: All groups (400 mg of ofloxacin daily, 800 mg of ofloxacin daily, and combination therapy)
Number of subjects: 24
Study: 2648691

Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of 200 mg Buflomedil
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 200 mg Buflomedil
Number of subjects: 42
Study: 29242238

Group type: EXPERIMENTAL
Intervention: Short telomere length (TL) in leukocytes (LTL)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Muscle telomere length adjusted for biopsy site (MTLA)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: TL gap between leukocytes and muscle (LTL-MTLA)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: TL ratio between leukocytes and muscle (LTL/MTLA)
Number of subjects: 259
Study: 26790833

Group type: EXPERIMENTAL
Intervention: Subinguinal approach
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High inguinal approach
Number of subjects: 81
Study: 24648482

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IV)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine administration (IP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (IP and IV saline)
Number of subjects: 72
Study: 22104642

Group type: EXPERIMENTAL
Intervention: +3.00 D IOL
Number of subjects: 20

Group type: COMPARATOR
Intervention: +4.00 D IOL
Number of subjects: 20
Study: 21309442

Group type: EXPERIMENTAL
Intervention: Individualized alpha bandwidths (broad and narrow sub-bands)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Antidepressant use in MDD group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional fixed 8-13 Hz alpha band
Number of subjects: 34
Study: 18678846

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0
Study: 16316485

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 30
Study: 14687444

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily
Number of subjects: 516

Group type: COMPARATOR
Intervention: Diclofenac 50 mg three times daily
Number of subjects: 516
Study: 11908375

Group type: EXPERIMENTAL
Intervention: Colgate Actibrush (battery-powered toothbrush)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Colgate Plus Diamond Head (manual toothbrush)
Number of subjects: 62
Study: 8960727

Group type: EXPERIMENTAL
Intervention: Oral 3,4 diaminopyridine (DAP) up to 100 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral 3,4 diaminopyridine (DAP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1561829

Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in previously unimmunized full-term children
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in sick and recovered reimmunized children
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in both cohorts
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in full-term children
Number of subjects: 63
Study: 4014870

Group type: EXPERIMENTAL
Intervention: 0.10 ppm O3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.15 ppm O3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.20 ppm O3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.25 ppm O3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intermittent heavy exercise (VE, 68 L/min) lasting 14 min every 30 min during exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cough, nose and throat irritation, and chest discomfort
Number of subjects: 20
Study: 30366845

Group type: EXPERIMENTAL
Intervention: Physical therapy trials with funding, conducted in Europe and Oceania, and with a Physiotherapy Evidence Database score of at least 6/10
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Physical therapy trials
Number of subjects: 200
Study: 28709680

Group type: EXPERIMENTAL
Intervention: CAD-CAM laser-sintered RPDs
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cast RPDs
Number of subjects: 12
Study: 27734089

Group type: EXPERIMENTAL
Intervention: SeLECT Defense™ sealant
Number of subjects: 50

Group type: COMPARATOR
Intervention: No sealant (control)
Number of subjects: 50
Study: 24928639

Group type: EXPERIMENTAL
Intervention: 12 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: 0 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 6 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 18 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400
Study: 23183149

Group type: EXPERIMENTAL
Intervention: Fingerstick rapid HIV testing
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Oral fluid rapid HIV testing
Number of subjects: 1651
Study: 20550024

Group type: EXPERIMENTAL
Intervention: 8 mg ramelteon
Number of subjects: 14
Study: 18568800

Group type: EXPERIMENTAL
Intervention: Solvent exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 20
Study: 17373561

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Treatment (ICBT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 12-Step Facilitation Therapy (TSF)
Number of subjects: 66
Study: 14619385

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 mcg/hr after a bolus of 50 mcg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vasopressin (0.4 units/min)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 10826430

Group type: EXPERIMENTAL
Intervention: Lithotomy position
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Removal of limbs from stirrups and placing them supine
Number of subjects: 8
Study: 8694297

Group type: EXPERIMENTAL
Intervention: Nasogastric tube managed by gravity drainage
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nasogastric tube managed by continuous low-grade suction
Number of subjects: 51

Group type: COMPARATOR
Intervention: No nasogastric tube (control)
Number of subjects: 51
Study: 1567342

Group type: EXPERIMENTAL
Intervention: Neutral‐liked conditioning with 10 acquisition trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral‐disliked conditioning with increasing acquisition trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized presentation schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blockwise presentation schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluative Style (Feelers vs Thinkers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contingency awareness
Number of subjects: 0
Study: 3893233

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Budesonide 400 micrograms twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 200 micrograms four times daily
Number of subjects: 20
Study: 31664476

Group type: EXPERIMENTAL
Intervention: Higher knowledge scores in women who heard about osteoporosis and had formal education
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Lower knowledge scores in women with certain conditions
Number of subjects: 560
Study: 29736638

Group type: EXPERIMENTAL
Intervention: Geldart group A
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Geldart group B
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Geldart group C
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Geldart group D
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sole UV photolysis
Number of subjects: 4
Study: 29028696

Group type: EXPERIMENTAL
Intervention: Intracranial pressure plus brain tissue oxygenation monitoring
Number of subjects: 119

Group type: COMPARATOR
Intervention: Intracranial pressure monitoring alone
Number of subjects: 119
Study: 26275650

Group type: EXPERIMENTAL
Intervention: 20-week Sun-style Tai Chi (TC) program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Education program (Control)
Number of subjects: 55
Study: 23978451

Group type: EXPERIMENTAL
Intervention: Flaxseed-enriched diet (10% flaxseed)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard diet (control)
Number of subjects: 100
Study: 21564519

Group type: EXPERIMENTAL
Intervention: Microhybrid composite (Esthet X; Dentsply/Caulk, Milford, DE, USA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nano composite (Ceram X; Dentsply/Caulk)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microhybrid composite reinforced with polyethylene fibre - flowable composite unit (Ribbond THM; Ribbond Inc., Seattle, WA, USA; Esthet X flow; Dentsply/Caulk)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with intact teeth (Group A)
Number of subjects: 40
Study: 17907049

Group type: EXPERIMENTAL
Intervention: Second-line hormone manipulation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Third-line hormone manipulation
Number of subjects: 65
Study: 16507016

Group type: EXPERIMENTAL
Intervention: Test seekers (141 participants)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Community-recruited blood donors (lapsed donors)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Accepted donors
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Rejected donors due to self-reported sexual risk
Number of subjects: 1600
Study: 15589870

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fenestration and coagulation (group 2)
Number of subjects: 100
Study: 11511714

Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 32
Study: 9313623

Group type: EXPERIMENTAL
Intervention: Verapamil and trandolapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trandolapril plus verapamil
Number of subjects: 0
Study: 8403792

Group type: EXPERIMENTAL
Intervention: Continuous visual analogue scaling of breathlessness during exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Discrete visual analogue scaling of breathlessness during exercise
Number of subjects: 6
Study: 3709628

Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 21
Study: 30661701

Group type: EXPERIMENTAL
Intervention: Personalized nutrition advice combined with vitamin K1, Ca and vitamin D
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care at the orthopedic ward (Control)
Number of subjects: 71
Study: 30126559

Group type: EXPERIMENTAL
Intervention: Baseline AF/AFL
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Incident AF/AFL
Number of subjects: 871
Study: 27669155

Group type: EXPERIMENTAL
Intervention: Lacosamide 200mg/day
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Lacosamide 400mg/day
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 24448173

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 119
Study: 22486728

Group type: EXPERIMENTAL
Intervention: Glass fibre post
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cast Ni‐Cr alloy post and core
Number of subjects: 80
Study: 20455882

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day with reduced-exposure CsA
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day with reduced-exposure CsA
Number of subjects: 833

Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) 1.44 g/day plus standard-exposure CsA
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Everolimus with progressive reduction in CsA exposure
Number of subjects: 833
Study: 17678730

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 103
Study: 15642018

Group type: EXPERIMENTAL
Intervention: Augmented visual feedback (FB) group using virtual reality (VR) system (DentSim)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No augmented feedback (no-FB) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study: 12142815

Group type: EXPERIMENTAL
Intervention: Ranitidine 5 mg/kg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ranitidine 10 mg/kg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ranitidine (both doses) and Omeprazole
Number of subjects: 22
Study: 10862313

Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (OGTT)
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Overall population without diabetes
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Known type-2 diabetes
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Newly detected type-2 diabetes
Number of subjects: 1198
Study: 7777127

Group type: EXPERIMENTAL
Intervention: Standardized clinical examination
Number of subjects: 1270
Study: 2155457

Group type: EXPERIMENTAL
Intervention: Ademetionin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 537572

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 12
Study: 30889096

Group type: EXPERIMENTAL
Intervention: 50 mg/d phytoSERM
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 100 mg/d phytoSERM
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 30204859

Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention (weekly dietetic consultation, energy-protein-enriched diet, and ONS 400 mL per day for 3 months)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual nutritional care (control)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention
Number of subjects: 152
Study: 26576820

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combination treatment (cognitive behavior therapy and fluoxetine)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 196
Study: 24988873

Group type: COMPARATOR
Intervention: 7-day PPI triple therapy
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 15-day sequential therapy
Number of subjects: 332
Study: 23148456

Group type: EXPERIMENTAL
Intervention: Integrating HIV care/treatment into family planning services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrating HIV care/treatment into postnatal care services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 0
Study: 19450880

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 15
Study: 17452677

Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 569

Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 569
Study: 15370581

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, daily subcutaneous injections for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 20
Study: 12405553

Group type: EXPERIMENTAL
Intervention: Melatonin (6mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Melatonin with Sunglasses (6mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10440909

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 75
Study: 7869203

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional intermittent mandatory ventilation (IMV)
Number of subjects: 26